Search

BACKGROUND The relevance of the IMPROVE-IT trial on real-life practice has not been explored in patients with ACS. METHODS A prospective Swiss cohort of 6266 patients hospitalized for ACS between 2009 and 2017 with a one-year follow-up. The primary endpoints were the ezetimibe use overall or in combination with high-intensity statin at discharge and at one year after ACS. Secondary endpoint was LDL-C target achievement at one year in a subsample of 2984 patients. Relative Ratios (RR) were used to assess changes in primary endpoints before and after the publication of IMPROVE-IT, adjusting for age, sex, diabetes, prior myocardial infarction, LDL-C and attendance to cardiac rehabilitation. RESULTS The period following the publication of the IMPROVE-IT trial was associated with a steady increase in the use of ezetimibe at discharge (from 1.8% to 3.8%, P

Background Many parameters can affect the level of inflammation during acute coronary syndromes (ACS). We aimed to assess the one-year risk of major adverse cardiovascular events (MACE) and bleeding associated with elevated hsCRP levels during ACS, taking into account the severity of myocardial infarction, the timing of blood sampling and established long-term prognostic factors. Methods We studied 1864 consecutive patients with ACS enrolled in a contemporary multicenter prospective cohort study in Switzerland. HsCRP levels were determined at hospital admission. One year after discharge MACE and bleeding events were assessed. Multivariable adjusted Cox proportional hazards were computed with age, sex, time from symptom onset to blood draw, body mass index, current smoking, hypertension, diabetes mellitus, pre-existing cardiovascular disease, history of inflammatory disease, LDL-cholesterol levels, type of ACS, left ventricular ejection fraction and GRACE 1.0 risk score. Results At one-year follow-up, 151 (8.1%) patients suffered MACE. Compared to patients with hsCRP below 2 mg/l, the risk of MACE was higher in patients with hsCRP levels between 2 and 5 mg/l, with a multivariate adjusted hazard ratio (HR) of 1.63 (95% confidence interval (CI) 0.93–2.84), in those with levels between 5 and 10 mg/l, with a HR of 2.80 (95% CI 1.58–4.96), and in those with levels above 10 mg/l, with a HR of 2.23 (95% CI 1.28–3.88). There was no difference in bleeding risk between the four groups. Conclusions Systemic inflammation in the acute phase of myocardial infarction is an independent predictor for cardiovascular events, but not for bleeding.

Aims: To analyze the diagnostic yield of 24-h electrocardiographic monitoring (Holter) as a function of cardiac disease and electrocardiography (ECG) status in patients with unexplained syncope. Methods: Patients were considered as having unexplained syncope when a careful clinical history, physical and neurological examination, 12-lead ECG and testing for orthostatic hypotension were negative. All patients underwent 24-h Holter. According to the type of arrhythmias that occurred during monitoring, Holter was classified as: (1) normal, in the absence of significant arrhythmias; (2) abnormal, in the presence of significant (e.g. atrial fibrillation) but non-diagnostic arrhythmias; or (3) diagnostic, in the presence of serious arrhythmia (e.g. complete AV block) with simultaneous symptoms. Clinical features, ECG and echocardiography were used to stratify patients and identify those in whom electrophysiological studies (EPS) were indicated. Results: 140 consecutive patients with unexplained syncope underwent 24-h Holter and 44 of them (31%) had non-diagnostic arrhythmias. These occurred more frequently in patients with a positive cardiac history or an abnormal ECG (31/73, 42%), compared to patients without these features (13/67, 19%, p